US2012190706A1PendingUtilityA1

Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof

43
Assignee: SCANIO MARC J CPriority: Mar 23, 2007Filed: Mar 23, 2012Published: Jul 26, 2012
Est. expiryMar 23, 2027(~0.7 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 25/18A61P 25/34A61P 25/00A61P 25/16A61P 25/28A61P 25/04A61P 29/00A61P 25/14C07D 471/18A61P 21/02
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention relates to compounds that are acetamide and carboxamide derivatives of azaadamantane, compositions comprising such compounds, and methods of using such compounds and compositions.

Claims

exact text as granted — not AI-modified
1 .- 8 . (canceled) 
     
     
         9 . A method for treating a disorder selected from the group consisting of mild cognitive impairment, age-associated memory impairment (AAMI), senile dementia, AIDS dementia, Pick's Disease, dementia associated with Lewy bodies, dementia associated with Down's syndrome, amyotrophic lateral sclerosis, Huntington's disease, smoking cessation, schizoaffective disorder, bipolar and manic disorders, diminished CNS function associated with traumatic brain injury, acute pain, post-surgical pain, chronic pain, and inflammatory pain, said method comprising the step of administering to a subject in need thereof the compound of the formula (I), or a pharmaceutically acceptable salt thereof, wherein the compound of formula I comprises: 
       
         
           
           
               
               
           
         
       
       wherein
 Y 1  is 
 
       
         
           
           
               
               
           
         
         A is aryl, heteroaryl, heterocycle, cycloalkyl, cycloalkenyl, arylalkyl, heteroarylalkyl, heterocyclealkyl, cycloalkylalkyl, or cycloalkenylalkyl wherein the aryl, heteroaryl, heterocycle, cycloalkyl, cycloalkenyl, the aryl moiety of arylalkyl, the heteroaryl moiety of the heteroarylalkyl, the heterocycle moiety of the heterocyclealkyl, the cycloalkyl moiety of the cycloalkylalkyl, and the cycloalkenyl moiety of the cycloalkenylalkyl are each independently unsubstituted or substituted; and 
         Y 2  is hydrogen or alkyl, 
         or a pharmaceutically acceptable salt thereof. 
       
     
     
         10 . A method for treating a disorder selected from the group consisting of attention deficit disorder, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), Parkinson's disease, Tourette's syndrome, schizophrenia, and cognitive deficits associated with schizophrenia (CDS), said method comprising the step of administering to a subject in need thereof the compound of  claim 9 , or a pharmaceutically acceptable salt thereof. 
     
     
         11 . A method for treating a disorder selected from the group consisting of schizophrenia and cognitive deficits associated with schizophrenia (CDS), or combination thereof, comprising the step of administering to a subject in need thereof the compound of  claim 9 , or a pharmaceutically acceptable salt and one or more atypical antipsychotics. 
     
     
         12 .- 13 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.